title: In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy.
abstract: As previously reported, ovarian epithelial carcinomas may respond to endocrine therapy. We examined the direct effect of progesterone, medroxyprogesteroneacetate, gestoneron, 17-beta-estradiol, tamoxifen, 4-OH-tamoxifen, or N-desmethyltamoxifen on the proliferative capacity of ovarian carcinoma cells by means of the colony assay described by Hamburger and Salmon. The growth rate of 25 tested tumors (ascitic fluid, primary tumor, metastases) was 68%. The plating efficiency was 0.078%. Beside the drug testing estrogen and progesterone receptor levels were determined. The inhibition of colony survival was slightest with 17-beta-estradiol, more pronounced with medroxyprogesteroneacetate, gestoneron, N-desmethyltamoxifen, and progesterone, and greatest with 4-OH-tamoxifen and tamoxifen. Significant and dose-dependent inhibition of greater than 70% was observed with tamoxifen and 4-OH-tamoxifen in 80% of the tested tumors. There was no significant correlation between the in vitro responsiveness and the level of hormonal act not only via an estrogen receptor but also via an antiestrogen-binding site.
authors.forename: H M
authors.initials: HM
authors.lastname: Runge
authors.forename: G
authors.initials: G
authors.lastname: Teufel
authors.forename: J
authors.initials: J
authors.lastname: Neulen
authors.forename: H
authors.initials: H
authors.lastname: Geyer
authors.forename: A
authors.initials: A
authors.lastname: Pfleiderer
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004958:Estradiol / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000431:Ethanol / Q000633:toxicity; D005260:Female; D005866:Gestonorone Caproate / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014411:Neoplastic Stem Cells / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011374:Progesterone / Q000494:pharmacology / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; C016601:afimoxifene; D000431:Ethanol; D011374:Progesterone; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; C028787:N-desmethyltamoxifen; D005866:Gestonorone Caproate